A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR

Manuscript Number: 

18-0749R1

Author(s): 
Jeffrey L. Gunter, Clifford R. Jack Jr., David S. Knopman, Val J. Lowe, Ronald C. Petersen, Christopher G. Schwarz, Matthew L. Senjem, Prashanthi Vemuri, Stephen D. Weigand

Disclosures

Jeffrey L. Gunter

  • Nothing to Disclose

Clifford R. Jack Jr.

  • Nothing to Disclose

David S. Knopman

  • Consulting Fees:
    DSMB for DIAN-TU study
    Grants
    • Agency: 
      Lilly, A4 study study site
      Dates: 
      2014 to 2022
    • Agency: 
      Biogen aducanumab study site
      Dates: 
      2016 to 2020

Val J. Lowe

  • Grants
    • Agency: 
      GE Heathcare
      Dates: 
      2004-2017
    • Agency: 
      Siemens Molecular Imaging
      Dates: 
      2007-2016
    • Agency: 
      AVID Radiopharmaceuiticals
      Dates: 
      2010- present

Ronald C. Petersen

  • Consulting Fees:
    Consultant for the following: Hoffman-La Roche, Inc. Merck, Inc. Genentech, Inc. Biogen, Inc.
    Lecture Fees:
    Presentation for GE Healthcare; $4800 for moderating a debate.
    Patents/Royalties
    Yes, royalties for book: “Mild Cognitive Impairment,” Oxford University Press, 2003

Christopher G. Schwarz

  • Nothing to Disclose

Matthew L. Senjem

  • Equity:
    Disclosures outside the submitted work: M.L.S. owns stocks in Align Technology, Inc., CRISPR Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson, LHC Group, Inc., Medtronic, Inc., Mesa Laboratories, Inc., Natus Medical Inc., and Varex Imaging Corporation.  MLS has owned these medical related stocks within the past three years, unrelated to the current work: Gilead Sciences, Inc., Globus Medical Inc., Inovio Biomedical Corp., Oncothyreon, Inc., Parexel International Corporation

Prashanthi Vemuri

  • Nothing to Disclose

Stephen D. Weigand

  • Nothing to Disclose